Archives | Selexis SA

December 17, 2018

Teneobio and Selexis Enter Second Services Agreement to Develop Research Cell Banks as Teneobio Prepares to Advance Three Additional Oncology-Targeting Multi-Specific UniAbs into the Clinic

December 03, 2018

KBI Biopharma Inc. and Selexis SA Form Joint Scientific Advisory Board

October 18, 2018

Selexis and Berkeley Lights Collaborate to Accelerate Cell Line Development with the Beacon Optofluidic Platform

September 26, 2018

Selexis and Hoba Therapeutics Team Up to Advance Hoba’s Investigational Neuropathic Pain Treatment into the Clinic

September 13, 2018

Meet with Selexis Scientific and Business Leaders at Several Upcoming Industry Conferences and Events

Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly-specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 100 partners worldwide, 85 drug products in clinical development and three commercial products utilizing Selexis-generated cell lines, the Company has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research.